Pharmaceutical Technology

JANUARY 19, 2023

Despite the challenges faced by gene-modified cell therapies such as CAR-T cells, significant promise remains for allogeneic cell therapies that have not been gene edited. If approved, it could reach sales of $158 million in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and China) by 2031.

Marketing 130

Marketing Gene Editing Production Sales 130

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing. per-share deal valuing GBT at $5.4

Marketing 111

Marketing Sales Gene Editing Antibody 111

Pharmaceutical Technology

JUNE 15, 2023

Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD). The company will receive a combined upfront payment and equity investment of $60m.

Gene Editing 130

Gene Editing Gene Gene Therapy In-Vivo 130

pharmaphorum

JANUARY 10, 2022

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. There is another $1 billion in downstream payments on offer, assuming the drug candidates all make it through to regulatory approval and hit sales targets.

In-Vivo 52

In-Vivo Gene Editing Gene Therapy Gene 52

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

pharmaphorum

JULY 13, 2021

The bulk of Novo Nordisk’s revenues come from its diabetes products, although it also active in the development and sale of drugs for growth disorders, haemophilia and sickle cell disease. According to analysts at GlobalData – sales are set to rocket to $3.5 All told, the deal could be worth up to $1.2 billion by 2025.

Gene Silencing 98

Gene Silencing Sales Gene Editing Clinical Trials 98

The Pharma Data

AUGUST 4, 2020

In addition, Oxford Biomedica is eligible to receive certain development and regulatory milestones for products sold by Beam that use the LentiVector platform and an undisclosed royalty on net sales of these products.

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

pharmaphorum

DECEMBER 14, 2022

The board helps Sixth Street’s healthcare and life sciences team to identify opportunities around CRISPR and gene editing. Global investment firm Sixth Street has added some big names to its advisory board: Verily’s Dr Amy Abernethy , epigenetics researcher Dr Steve Jacobsen , and geneticist Dr Jay Shendure. Other agency hires.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

pharmaphorum

FEBRUARY 17, 2022

Sales of Oxbryta was a little slow to gather momentum, mainly because of payer resistance in the US, but are starting to ramp up, rising 41% to $52 million in the third quarter of 2021. The resulting damage to tissues and organs can lead to life-threatening complications including stroke and irreversible organ damage.

Drugs 59

Drugs Gene Therapy Gene Editing Gene 59

XTalks

FEBRUARY 8, 2024

The awarding of the Nobel Prize in Chemistry in 2020 to Jennifer Doudna and Emmanuelle Charpentier for their development of CRISPR-Cas9 gene-editing technology is a prime example of the extraordinary achievements of women in science.

Life Science 105

Life Science Scientist Gene Editing Research 105

Delveinsight

MARCH 2, 2021

To sum it, Chinook will manage clinical development and commercialization of product candidates while Evotec will be eligible for an undisclosed upfront payment, research funding, progress-dependent milestone payments, and tiered royalties on net sales for targets identified through the collaboration.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

The Pharma Data

JANUARY 17, 2021

Genus’s worldwide sales are made in over 80 countries under the trademarks ‘ABS’ (dairy and beef cattle) and ‘PIC’ (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms.

Containment 52

Containment Genetics Gene Editing Production 52

The Pharma Data

JANUARY 17, 2021

Unlike investigational gene therapies and gene editing approaches which require fully myeloablative conditioning, the unique characteristics of ARU-1801 allow it to be given with reduced intensity conditioning (“RIC”). The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6

Manufacturing 52

Manufacturing Gene Therapy Trials Gene 52

pharmaphorum

JULY 13, 2022

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment. dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine. Today: we are announcing.

Gene Editing 98

Gene Editing Trials Drugs Gene 98

XTalks

DECEMBER 29, 2022

In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. The therapy, exagamglogene autotemcel (exa-cel), was granted a rolling review by the FDA.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JANUARY 4, 2024

Gene therapy approvals for rare blood disorders like sickle cell disease and beta thalassemia have been gaining traction lately, with two significant approvals in sickle cell disease recently — CRISPR Therapeutics and Vertex Pharmaceuticals’ CRISPR gene editing drug Casgevy (exa-cel) and bluebird bio’s viral vector therapy Lyfgenia (lovo-cel).

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

The Pharma Data

MARCH 13, 2021

With an estimated peak sales value of up to 30 billion euros, Bayer has the most productive pipeline in the industry, continually converting its industry leading value-driven investment into new, innovative products that benefit growers, consumers and the planet.

Production 40

Production Development Marketing Gene Editing 40

The Pharma Data

MARCH 11, 2021

The company is taking steps aimed at strengthening sales growth, profitability and free cash flow. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. Speeding up sales growth. through 2023.

Sales 52

Sales Gene Therapy Marketing Gene 52

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients.

Manufacturing 52

Manufacturing Production Development Clinical Trials 52

Drug Discovery World

FEBRUARY 28, 2023

offer unique imaging capabilities that will vastly improve organoid imaging, IVF imaging, viral plaque assays, gene editing (CRISPR), and stem cell production for researchers,” explained Thomas Farb-Horch, CEO of Thrive. . “The CellAssist family of products, including and software Release 4.0,

Gene Editing 52

Gene Editing Production Scientist Contamination 52

The Pharma Data

NOVEMBER 24, 2020

The adoption and sales of ABS’ sexed and beef-on-dairy products, Sexcel ® and NuEra ® , continued to grow rapidly as planned, with strong growth in volumes across multiple geographies. Sales via a digital channel introduced in Latin America during the COVID-19 lockdown period have continued to contribute well in the new financial year.

Genetics 40

Genetics Containment Sales Production 40

Drug Discovery World

OCTOBER 7, 2022

In terms of new modalities, we will develop our small molecule and antibody capabilities but also evaluate our scope to support the creation of next-generation therapies, including nucleic acids and gene editing. . RA: What’s the future outlook for Cancer Research Horizons? .

HR 52

HR Research Drugs Development 52

Pharmaceutical Technology

MARCH 2, 2023

The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing. Additionally, Vertex will pay tiered royalties to ImmunoGen as a percentage of global commercial sales of new conditioning agents.

Gene Editing 130

Gene Editing Gene Development Research 130